Peroxisome proliferator-activated receptors: From transcriptional control to clinical practice

Current Opinion in Lipidology

Volumn 12, Issue 3, 2001, Pages 245-254

  Torra, Inés Pineda ^a   Chinetti, Giulia ^a   Duval, Caroline ^a   Fruchart, Jean Charles ^a   Staels, Bart ^a  

^a INSTITUT PASTEUR DE LILLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BILE ACID; CHOLESTEROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; TRANSCRIPTION FACTOR;

ADIPOCYTE; ATHEROSCLEROSIS; BILE ACID SYNTHESIS; CARDIOVASCULAR DISEASE; CELL FUNCTION; CHOLESTEROL TRANSPORT; CLINICAL PRACTICE; DYSLIPIDEMIA; GENE TARGETING; GLUCOSE HOMEOSTASIS; HOMEOSTASIS; HUMAN; INSULIN RESISTANCE; LIPID METABOLISM; LIPOPROTEIN METABOLISM; METABOLIC DISORDER; NONHUMAN; OBESITY; PRIORITY JOURNAL; REVIEW; TRANSCRIPTION REGULATION;

ANIMALS; BIOLOGICAL TRANSPORT; CHOLESTEROL; FATTY ACIDS; FOAM CELLS; HUMANS; LIGANDS; LIPID METABOLISM; MICE; MODELS, BIOLOGICAL; PROTEIN PROCESSING, POST-TRANSLATIONAL; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; TRIGLYCERIDES;

EID: 0034993832     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041433-200106000-00002     Document Type: Review

References (110)

1. Peroxisome proliferator-activated receptors: Nuclear control of metabolism
2. Peroxisome proliferator-activated receptor beta regulates acyl-CoA synthetase 2 in reaggregated rat brain cell cultures
3. Alterations of peroxisome proliferator-activated receptor delta activity affect fatty acid-controlled adipose differentiation
4. Peroxisome-proliferator-activated receptor delta mediates the effects of long-chain fatty acids on post-confluent cell proliferation
5. PPARdelta-mediated regulation of preadipocyte proliferation and gene expression is dependent on cAMP signaling
6. Peroxisome proliferator-activated receptors (PPARs): Nuclear receptors at the crossroads between lipid metabolism and inflammation
7. Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1
8. Oxidized low density lipoprotein inhibits interleukin-12 production in lipopolysaccharide-activated mouse macrophages via direct interactions between peroxisome proliferator-activated receptor-gamma and nuclear factor-kappa B
9. Activation of human T lymphocytes is inhibited by peroxisome proliferator-activated receptor gamma (PPARgamma) agonists. PPARgamma co-association with transcription factor NFAT
10. Induction of IkBalpha expression as a mechanism contributing to the anti-inflammatory activities of peroxisome proliferator-activated receptor-alpha activators
11. The PPARs: From orphan receptors to drug discovery
12. Lipid-binding proteins modulate ligand-dependent trans-activation by peroxisome proliferator-activated receptors and localize to the nucleus as well as the cytoplasm
13. Phytanic acid activates the peroxisome proliferator-activated receptor alpha (PPARalpha) in sterol carrier protein 2-/ sterol carrier protein x-deficient mice
14. Pristanic acid and phytanic acid. Naturally occurring ligands for the nuclear receptor peroxisome proliferator-activated receptor alpha
15. Conjugated linoleic acid is a potent naturally occurring ligand and activator of PPARalpha
16. Oxidized phospholipids activate PPARalpha in a phospholipase A2-dependent manner
17. Novel peroxisome proliferator-activated receptor (PPAR) gamma and PPARdelta ligands produce distinct biological effects
18. Crystal structure of the ligand binding domain of the human nuclear receptor PPARgamma
19. Molecular recognition of fatty acids by peroxisome proliferator-activated receptors
20. Asymmetry in the PPARgamma/RXRalpha crystal structure reveals the molecular basis of heterodimerization among nuclear receptors
21. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma
22. Both coactivator LXXLL motif-dependent and -independent interactions are required for peroxisome proliferator-activated receptor gamma (PPARgamma) function
23. N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 3. Structure-activity relationship and optimization of the N-aryl substituent
24. A novel N-aryl tyrosine activator of peroxisome proliferator-activated receptor-gamma reverses the diabetic phenotype of the Zucker diabetic fatty rat
25. A peroxisome proliferator-activated receptor gamma ligand inhibits adipocyte differentiation
26. A synthetic triterpenoid, 2-cyano-3 12-dioxooleana-1,9-dien-28-oic acid (CDDO), is a ligand for the peroxisome proliferator-activated receptor gamma
27. A selective peroxisome proliferator-activated receptor-gamma (PPARgamma) modulator blocks adipocyte differentiation but stimulates glucose uptake in 3T3-L1 adipocytes
28. A potent antidiabetic thiazolidinedione with unique peroxisome proliferator-activated receptor gamma-activating properties
29. Euglycemic and hypolipidemic activity of PAT5A: A unique thiazolidinedione with weak peroxisome proliferator activated receptor gamma activity
30. Differential activation of peroxisome proliferator-activated receptor-gamma by troglitazone and rosiglitazone
31. Regulation of gene expression in vivo by PPAR gamma
32. Treatment of insulin resistance with peroxisome proliferator-activated receptor gamma agonists
33. Nuclear receptor cofactors as chromatin remodelers
34. Peroxisome proliferator-activated receptors and retinoic acid receptors differentially control the interactions of retinoid X receptor heterodimers with ligands, coactivators, and corepressors
35. Stoichiometric and steric principles governing repression by nuclear hormone recptors
36. Identification of nuclear receptor corepressor as a peroxisome proliferator-activated receptor alpha interacting protein
37. Discrete roles for peroxisome proliferator-activated receptor gamma and retinoid X receptor in recruiting nuclear receptor coactivators
38. An adipogenic cofactor bound by the differentiation domain of PPARgamma
39. Identification of ARA70 as a ligand-enhanced coactivator for the peroxisome proliferator-activated receptor gamma
40. Specific structural motifs determine TRAP220 interactions with nuclear hormone receptors
41. Isolation and characterization of peroxisome proliferator-activated receptor (PPAR) interacting protein (PRIP) as a coactivator for PPAR
42. Activation of PPARgamma coactivator-1 through transcription factor docking
43. p120 acts as a specific coactivator for 9-cis-retinoic acid receptor (RXR) on peroxisome proliferator-activated receptor-gamma/RXR heterodimers
44. A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis
45. Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1
46. Peroxisome proliferator-activated receptor gamma coactivator-1 promotes cardiac mitochondrial biogenesis
47. The coactivator PGC-1 cooperates with peroxisome proliferator-activated receptor alpha in transcriptional control of nuclear genes encoding mitochondrial fatty acid oxidation enzymes
48. Deletion of PBP/PPARBP, the gene for nuclear receptor coactivator peroxisome proliferator-activated receptor-binding protein, results in embryonic lethality
49. The peroxisome proliferator-activated receptor alpha is a phosphoprotein: Regulation by insulin
50. Regulation of the transcriptional activity of the peroxisome proliferator-activated receptor alpha by phosphorylation of a ligand-independent transactivating domain
51. Insulin- and mitogen-activated protein kinase-mediated phosphorylation and activation of peroxisome proliferator-activated receptor gamma
52. Regulation of peroxisome proliferator-activated receptor gamma activity by mitogen-activated protein kinase
53. c-Jun N-terminal kinase phosphorylates peroxisome proliferator-activated receptor-gamma1 and negatively regulates its transcriptional activity
54. Transforming growth factor-beta1 (TGF-beta1) and TGF-beta2 decrease expression of CD36, the type B scavenger receptor, through mitogen-activated protein kinase phosphorylation of peroxisome proliferator-activated receptor-gamma
55. Negative regulation of peroxisome proliferator-activated receptor-gamma gene expression contributes to the antiadipogenic effects of tumor necrosis factor-alpha
56. Activation of peroxisome proliferator-activated receptors (PPARs) by their ligands and protein kinase A activators
57. Degradation of the peroxisome proliferator-activated receptor gamma is linked to ligand-dependent activation
58. Peroxisome proliferator-activated receptor alpha-isoform deficiency leads to progressive dyslipidemia with sexually dimorphic obesity and steatosis
59. PPAR gamma is required for placental, cardiac, and adipose tissue development
60. PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance
61. PPAR gamma is required for the differentiation of adipose tissue in vivo and in vitro
62. Improved insulin-sensitivity in mice heterozygous for PPAR-gamma deficiency
63. Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor beta(delta)
64. Hepatocyte-specific mutation establishes retinoid X receptor alpha as a heterodimeric integrator of multiple physiological processes in the liver
65. Peroxisome proliferator-activated receptor alpha-mediated pathways are altered in hepatocyte-specific retinoid X receptor alpha-deficient mice
66. Impaired adipogenesis and lipolysis in the mouse upon selective ablation of the retinoid X receptor alpha mediated by a tamoxifen-inducible chimeric Cre recombinase (Cre-ERT2) in adipocytes
67. Variation in the PPARα gene is associated with altered function in vitro and plasma lipid concentrations in type II diabetic subjects
68. Molecular scanning of the human PPARalpha gene: Association of the L162V mutation with hyperapobetalipoproteinemia
69. The human peroxisome proliferator-activated receptor alpha gene: Identification and functional characterization of two natural allelic variants
70. Mutation screening of the PPARalpha gene in type 2 diabetes associated with coronary heart disease
71. A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity
72. The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes
73. Obesity associated with a mutation in a genetic regulator of adipocyte differentiation
74. Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension
75. Peroxisome proliferator-activated receptor alpha mediates the adaptive response to fasting
76. A critical role for the peroxisome proliferator-activated receptor alpha (PPARalpha) in the cellular fasting response: The PPARalpha-null mouse as a model of fatty acid oxidation disorders
77. Defect in peroxisome proliferator-activated receptor alpha-inducible fatty acid oxidation determines the severity of hepatic steatosis in response to fasting
78. Reduced hepatic fatty acid oxidation in fasting PPARalpha null mice is due to impaired mitochondrial hydroxymethylglutaryl-CoA synthase gene expression
79. The effect of ethanol on the beta-oxidation of fatty acids
80. The transcriptional and DNA binding activity of peroxisome proliferator-activated receptor alpha is inhibited by ethanol metabolism
81. Deactivation of peroxisome proliferator-activated receptor-alpha during cardiac hypertrophic growth
82. PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL
83. PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation
84. The role of PPAR-gamma in macrophage differentiation and cholesterol uptake
85. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma
86. PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway
87. Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency
88. The Tangier disease gene product ABC1 controls the cellular apolipoprotein-mediated lipid removal pathway
89. CLA-1/SR-BI is expressed in atherosclerotic lesion macrophages and regulated by activators of peroxisome proliferator-activated receptors
90. A PPARgamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis
91. Mechanism of action of fibrates on lipid and lipoprotein metabolism
92. Activation of PPARdelta alters lipid metabolism in db/db mice
93. A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport
94. Cross-talk between fatty acid and cholesterol metabolism mediated by liver X receptor-alpha
95. The role of orphan nuclear receptors in the regulation of cholesterol homeostasis
96. Effects of treatment with clofibrate, bezafibrate, and ciprofibrate on the metabolism of cholesterol in rat liver microsomes
97. Influence of bezafibrate on hepatic cholesterol metabolism in gallstone patients: Reduced activity of cholesterol 7 alpha-hydroxylase
98. Effects of different phenotypes of hyperlipoproteinemia and of treatment with fibric acid derivatives on the rates of cholesterol 7 alpha-hydroxylation in humans
99. Peroxisome proliferator-activated receptor alpha (PPARalpha) and agonist inhibit cholesterol 7alpha-hydroxylase gene (CYP7A1) transcription
100. The effect of peroxisome-proliferator-activated receptor-alpha on the activity of the cholesterol 7alpha-hydroxylase gene
101. The murine and human cholesterol 7alpha-hydroxylase gene promoters are differentially responsive to regulation by fatty acids mediated via peroxisome proliferator-activated receptor alpha
102. The peroxisome proliferator-activated receptor alpha (PPARalpha) regulates bile acid biosynthesis
103. Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice
104. Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes
105. Effects of troglitazone on frequency of coronary vasospastic-induced angina pectoris in patients with diabetes mellitus
106. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients
107. Cardiovascular outcomes in type 2 diabetes. A double-blind placebo-controlled study of bezafibrate: The St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study
108. Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol
109. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol
110. Status report of lipid-lowering trials in diabetes